1

2	Molecular and spatial epidemiology of HCV among people who inject drugs in Boston,
3	Massachusetts
Д	
5	Thomas J. Stopka, PhD, MHS, ¹ Omar Yaghi, MD, MPH, ¹ Min Li, PhD, ² Elijah Paintsil, MD, ^{2,3} Kenneth Chui, PhD, MPH, ¹ David Landy, MSPH, ¹ and Robert Heimer, PhD ^{2,4}
/ 8	Affiliations
9 10 11	¹ Department of Public Health and Community Medicine, Tufts University School of Medicine ² Yale University School of Public Health ³ Yale New Haven Hospital
12 13	⁴ Center for Interdisciplinary Research on AIDS at Yale
14 15 16	
17 18 19	Corresponding Author: Robert Heimer, PhD
20 21 22	Professor of Epidemiology Department of Epidemiology of Microbial Diseases Yale University School of Public Health
23 24	60 College St. PO Box 208034
25 26 27	New Haven, CT 06520-8034 Phone: (203) 785-6732 Email: robert heimer@vale.edu
28 29	
30 31 22	Running Title: HCV Molecular Spatial Epidemiology: PWID
32 33 34	Abstract Word Count: 100 Manuscript Word Count: 2,020
35 36 37	Tables/Figures: 2 References: 17
38	

Λ	n
4	υ

Л	1
+	-

Abstract

42

43	Integration of genetic, social network, and spatial data has the potential to improve
44	understanding of transmission dynamics in established HCV epidemics. Sequence data
45	were analyzed from 63 viremic people who inject drugs recruited in the Boston area through
46	chain referral or time-location sampling. HCV subtype 1a was most prevalent (57.1%),
47	followed by subtype 3a (33.9%). The phylogenetic distances between sequences were no
48	shorter comparing individuals within versus across networks, nor by location or time of first
49	injection. Social and spatial networks, while interesting, may be too ephemeral to inform
50	transmission dynamics when the date and location of infection are indeterminate.
51	Keywords: HCV, people who inject drugs, phylogenetic analyses, spatial analyses, social
52	networks.
53	

55 INTRODUCTION

Although now curable, hepatitis C virus (HCV) infections continue to be problematic. 56 In the United States, HCV mortality has increased in recent years, while mortality for 61 57 other federally reportable infectious diseases, including HIV, has decreased.¹ HCV infections 58 have increased by more than 70% among 15-30 year-olds during the past decade, and new 59 60 infections are largely attributed to injection drug use (IDU).^{1,2} In Massachusetts, over 2,000 new cases attributed to IDU have been reported in those <30 years of age in each of the last 61 seven years.³ More information about transmission networks might improve prevention 62 63 efforts.

The application of phylogenetic and spatial analysis of HCV has identified HCV 64 subtypes among people who inject drugs (PWID) and provided biological evidence of 65 disease clusters and transmission patterns in outbreaks.⁴⁻⁶ We aimed to find evidence of 66 disease clusters or transmission patterns among PWID outside of known outbreaks. As part 67 of a study of PWID in the Boston area, we identified a subsample with active HCV infection 68 and sequenced part of their viral genome. We then integrated behavioral, social network, 69 spatial, and HCV phylogenetic data to explore transmission dynamics in established 70 epidemics. We were especially interested to see if we could find evidence of disease 71 clusters or transmission patterns that could identify potential targets, methods, or venues for 72 HCV prevention and treatment interventions. 73

74 METHODS

We employed a cross-sectional design focused on PWID in the Boston area. PWID were eligible if they met the following criteria: (1) age 15-45 years; (2) English or Spanish speaking; (3) evidence of track marks; (4) living with, at risk for, or infected with and subsequently cleared HCV; and (5) ability to provide written informed consent. The study protocol was approved by the [Blinded] Institutional Review Board and the [Blinded] Human

Investigation Committee. Consenting individuals completed a survey and were administered
the Oraquick® HCV Rapid Antibody test (OraSure Technologies).

Between February and October 2016, recruitment relied on time-location sampling 82 and chain referral in Boston and Cambridge. For the *time-location sampling* approach, 83 trained outreach staff recruited participants through partnership with harm reduction 84 85 programs, shelters, and social service agencies. Staff members at community-based agencies posted study flyers and identified PWID whom they knew were likely to have 86 acquired HCV and would be interested in participating in the study. For the *chain-referral* 87 approach, enrolled participants (i.e., "seeds") were asked to refer peers within their 88 89 networks to the study. In both approaches, research staff described the study to interested 90 recruits, confirmed participant eligibility, provided written materials, and obtained written 91 informed consent. Analysis of recruitment chains was depicted using the StatNet and UserNetR packages in R. 92

93 Participants were tested for HCV antibodies and then completed the survey on a tablet, laptop, or desktop computer in our research offices or on tablets or laptops in private 94 95 spaces provided by community-based partners. Surveys covering demographic, health, and 96 socio-behavioral topics were conducted in English or Spanish and lasted approximately 60 97 minutes. Participants were informed of HCV test results after completing the survey, and those who tested positive were invited to a separate appointment and were consented to 98 99 have a blood sample taken. Sample collection continued until 102 individuals were enrolled in the sub-study of HCV-positive participants. 100

Blood specimens were centrifuged, and the serum was added to RNA*Later*® to preserve the integrity of viral RNA (RNALater; Ambion Inc., Austin, TX). Samples were stored at -80°C. After thawing, viral RNA was purified and a 360-base region in the core gene was amplified and sequenced to identify genotypes and produce phylogenetic trees. We optimally aligned the nucleotide sequences using the CLUSTAL W program and constructed a phylogenetic tree by the Neighbor-Joining method based on Kimura's two-

parameter distances (Mega software, version 7.0). We assessed the reliability of the tree topologies by bootstrapping with 100 replicates, with a bootstrap agreement of \geq 70% required to define a phylogenetic cluster. Evolutionary distances were computed using the Maximum Composite Likelihood method.⁷

We compared sequence similarity by recruitment pattern, location of injection 111 112 initiation, and number of years injecting drugs. We conducted Fisher's exact tests to assess whether differences in HCV subtypes by recruitment approach were statistically significant. 113 We subsequently ran simple logistic regression analyses to determine whether place of 114 residence at the time of first injection or number of years injecting was significantly 115 116 associated with HCV subtypes. Place of residence was divided into three categories: 117 Boston, suburbs of Boston (i.e., outside of the city limits and on a Massachusetts Bay Transit Authority (MBTA) line), or beyond the suburbs (not reachable by MBTA line). The number of 118 years injecting was also divided into three categories: 0-5, 6-10, >10 years. 119

120 **RESULTS**

Among the 102 participants who tested positive for HCV antibodies and provided a 121 122 subsequent blood sample, 66 were actively infected and sequence data were obtained from 63 of the 66. Out of these 63, 60 completed the survey, and one additional participant 123 124 completed the survey without providing sequence data. Thus, the sample sizes are 63 for the sequence data and 61 for the survey. The mean age of the 61 respondents was 32±6 years, 125 and males comprised 75% of the sample. Forty (66%) described themselves as White non-126 Latino, nine as Latino, eight as mixed-race or other, and four as African American. Most were 127 128 single, with 42 (69%) living alone and 9 (15%) living with a partner. About three-quarters (n=46) reported their sexual orientation as heterosexual, nine as bisexual, and six as gay or 129 lesbian. Three-guarters of the sample reported being homeless and the median monthly 130 income was \$500-1000. Ninety percent (n=53) reported having been incarcerated. The mean 131 132 duration of IDU was 12 years (SD=8) (Table 1).

133 HCV subtype by recruitment pattern

Figure 1A shows the participant network. Thirty-one of the 63 participants were 134 identified through chain referral, indicated by being connected with double-headed arrows, 135 and 32 were identified through time-location sampling, indicated by nodes without 136 connection. Genotype 1a was higher for time-location participants (56.3%; 18/32) than for 137 138 chain referred participants (41.9%; 13/31; p-value: 0.211); genotype 3a was higher for chain referred participants (45.2%; 14/31) than for time-location participants (22.6%; 7/32; p-value: 139 0.109). While there was no exclusive clustering of subtypes within the chain referral clusters, 140 three clusters with n>3 only consisted of two subtypes. In addition, in the largest clusters 141 142 (n=13), seven participants with subtype 3a were connected.

143 HCV subtype by location of first injection

Among PWID with Subtype 1a, 32.4% (11/34) first injected in Boston, 20.6% (7/34) 144 first injected in Boston suburbs, and 47.1% (16/34) first injected outside of the Boston 145 suburbs. Among PWID with subtype non-1a, 39.1% (9/23) first injected in Boston, 30.4% 146 (7/23) first injected in Boston suburbs, and 30.4% (7/23) first injected outside of the suburbs. 147 148 Location of the first injection was not associated with HCV subtype, when comparing 149 subtypes from outside of the Greater Boston Area (odds ratio [OR]: 1.87; 95% confidence 150 interval [CI]: 0.54, 6.53) or in Boston suburbs (OR: 0.82; 95% CI: 0.21, 3.26) to subtypes from Boston. 151

152 HCV subtype by number of years injecting

Among PWID with Subtype 1a, 21.9% (7/32) had been injecting for 0-5 years, 31.3% (10/32) had injected for 6-10 years, and 46.9% (15/32) had been injecting for >10 years. Among PWID with Subtype Non-1a, 13.7% (3/22) had been injecting for 0-5 years, 13.7% (3/22) had injected for 6-10 years, and 72.7% (16/22) had been injecting for >10 years. We divided the sample into those infected with genotype 1a versus not 1a, and there was no difference between groups by years of injection experience (OR: 0.97, 95% CI: 0.90, 1.04).

159 HCV sequencing results

160 Sequencing results indicated that the distances between sequences in phylogenetic 161 analyses were no shorter comparing sequence data within versus across networks (Figure 162 1B). Four of the oldest injectors in the sample (individuals born in 1977 or earlier) were 163 infected with HCV genotypes 1b and 2b. Only one other individual was infected with either of 164 these two subtypes (Figure 1B).

165 DISCUSSION

Integrating social network, spatial, and molecular data from established epidemics 166 poses unique challenges. These stem from the lack of defined dates of infection, the 167 durability of current social network connections, the multilevel nature of risk environments,^{8,9} 168 169 and missing data about the full network structure that is obtained when chain referral 170 relationships are the sole data source on social connections. For this reason, we sought to determine if HCV was more closely related (1) when specimens were obtained from within 171 recruitment chains than those obtained by the less directed recruitment achieved by time-172 location sampling, and (2) when participants were categorized by time and location that their 173 174 first exposure to HCV had likely have occurred. For the latter analysis, we made the working 175 hypothesis that HCV infection is an early consequence of initiating (IDU). This hypothesis is consistent with observations of high HCV incidence in the first year of injection.^{10,11} 176

177 Our findings that HCV subtype 1a was the predominant subtype among PWID in the 178 Boston Area (57.1%), followed by subtype 3a (33.9%), differs from studies elsewhere that focused on HCV among PWID. A study from New York, conducted twenty years earlier than 179 180 ours, found that the predominant genotypes were 1a and 1b, with 3a comprising only 5% of sequences genotyped.¹² A study from Baltimore, concurrent with ours, found no evidence of 181 genotype 3a.¹³ Our study population was substantially younger than those in the other two 182 183 studies, consistent with our aim to recruit a younger sample, but differences in genotype were not associated with age. However, there were two subtypes (1b and 2b) that were 184

restricted to older individuals. It appears, however, that these subtypes have failed to spread
among younger members of our study population. Analysis of HCV genotypes from PWID in
Vancouver revealed a pattern similar to ours, with nearly half their sample infected with
genotype 1a and one-third infected with genotype 3a, but the relevance of this finding is
limited by the geographic distance between coasts.⁶

190 HCV phylogenetic clustering has been found in those recently initiating drug injection. Clustering was quite common in the large HIV-HCV outbreak in Scott County, Indiana. But 191 even there, multiple introductions of HCV were identified. Genotypes 1a and 3b accounted 192 for 72% and 20% of the patient samples, respectively, but additional genotypes had entered 193 194 the mix, and some people were infected with multiple genotypes.¹⁴ One study from Melbourne found within-network correlation with HCV genotype, but only in individuals 195 infected with genotype 3 and reporting recent drug injection initiation.¹⁵ In our study, we did 196 not find any significant associations between HCV subtypes by recruitment types, number of 197 years injecting, nor location of first injection. 198

Several limitations should be considered in interpreting our findings. First, our sample 199 is small and needs to be expanded. Second, while we aimed to use respondent driven 200 201 sampling (RDS), we ultimately used a modified RDS approach combined with a time-location sampling approach to recruit our sample during a relatively tight timeframe based on funding 202 203 requirements. Third, we used self-reported measures from our survey. Some questions we 204 asked referred to events from the distant past (e.g., place where first injected, date of first injection), which could have introduced recall bias. Fourth, our results are not generalizable 205 206 to the entire Boston Area, nor to other cities. Finally, although we sought to recruit a relatively young sample of PWID, many people had long injecting experiences, so their 207 208 social networks at the time they were infected with HCV may have been different from their social networks at the time of the survey. In lieu of trying to design studies that collect 209 210 detailed individual network and phylogenetics to reconstruct patterns of disease 211 transmission, it may be more reasonable to collect information sufficient to populate random

212 mixing and other forms of stochastic models.¹⁶ Sequencing of infectious disease

transmission among PWID may be most effective in the case of disease outbreaks.¹⁷

214 Conclusion

Social networks, while interesting, are too ephemeral to inform transmission dynamics if the date and location of infection are indeterminate. Expanding research efforts to obtain extensive social network data from PWID populations in established epidemics may not be worthwhile or cost-effective given the expense of obtaining full social network data. Alternatives, such as quasi network data obtained through RDS and random mixing models, may be sufficient when modeling transmission networks.

221

222 Acknowledgments

The authors wish to acknowledge the assistance of the following agencies and individuals who contributed to recruitment and data collection efforts through participant referrals or provision of space for data collection activities: AHOPE, AIDS Action Committee, South Boston Behavioral Health Center, Dr. Laura Grubb, Tufts Medical Center, and St. Anthony's Shelter. The authors also wish to thank Dr. Nadia Abdala for guidance on HCV specimen sequencing and preparation for phylogenetic analyses.

229 Funding Support

This research was funded by a 2016 grant from the Tufts Institute for Innovation (PI:
Stopka). Additional support was provided by the Providence-Boston Center for AIDS
Research (PI: Stopka), through Grant Number P30AI042853 from the National Institute of
Allergy and Infectious Diseases. Support for Dr. Heimer was provided through Grant Number
R01DA030420 from the National Institute on Drug Abuse. The content is solely the
responsibility of the authors and does not necessarily represent the official views of the
National Institute of Allergy and Infectious Diseases or the National Institute of Health.

237

238 Conflicts

239 The authors report no conflicts of interest.

240

241 Contributions

- TS conceptualized the study, oversaw all study activities, wrote the initial draft of the
- 243 manuscript, and obtained the funding for the study. OY assisted with field operations, data
- collection, data management, and review of the final manuscript. ML conducted phylogenetic
- analyses, development of data visualizations, and interpretation of findings. EP oversaw all
- laboratory analyses and interpretation of phylogenetic analyses. KC conducted statistical
- analyses and assisted with the development of all figures. DL coordinated field activities,
- 248 including recruitment, data collection, and data management. RH contributed to study
- conceptualization, the analytical plan, phylogenetic analyses, and interpretation of findings.
- All authors contributed to, reviewed, and approved the final version of the manuscript.

Table. Descriptive statistics: People who inject drugs in the Greater Boston Area of Massachusetts, 2016 (n=61).

	Total
	N=61
Age (year)	32 (6)
Gender	
Male	46 (75%)
Female	15 (25%)
Race/ethnicity	
African American	4 (7%)
American Indian/Alaskan Native	1 (2%)
Hispanic, Latino, or Latina	9 (15%)
White, non-Hispanic	40 (66%)
Mixed races & others	7 (11%)
Marital status	
Single/living alone	42 (69%)
Single, living w/ partner	9 (15%)
Married/ in domestic partnership	2 (3%)
Divorced	3 (5%)
Separated	3 (5%)
Widowed	2 (3%)
Sexual orientation	
Heterosexual/straight	46 (75%)
Gav/lesbian	6 (10%)
Bisexual	9 (15%)
Education level	
Grade 6-8	3 (5%)
Grade 9-12, not HS grad	14 (23%)
HS grad/GED	32 (52%)
Some colleage, no degree	9 (15%)
2-4 vrs college degree	1 (2%)
Graduate/professional degree	2 (3%)
Homeless	
No	15 (25%)
Yes	46 (75%)
Main residence. last 30 days	
Own apartment, house, or room	7 (11%)
Home of parents, relatives, or friends	10 (16%)
Halfway house, group home, or foster home	6 (10%)
Hotel or motel	2 (3%)
Shelter	18 (30%)
Abandoned building	2 (3%)
Public park	4 (7%)
Street, wooded area	7 (11%)
Other	5 (8%)
Income, last 30 days	
None	7 (11%)
< \$500	17 (28%)
\$500 to < \$1000	22 (36%)
\$1000 to < \$2000	8 (13%)
\$2000 to < \$4000	4 (7%)
\$4000 to < \$6000	1 (2%)
>= \$6000	2 (3%)
Ever in jail, prison, JDC	
No	6 (10%)
Yes	55 (90%)
Currenity on parole	
No	53 (87%)
Yes	8 (13%)



Figure 1. A) Network diagram showing the referral network. The different node symbols 257 represent the five major hepatitis C virus (HCV) subtypes. The double-headed arrows 258 259 indicate connection by referral (n=31). B) Phylogenetic tree for HCV positive people who inject drugs in Boston, Massachusetts, 2016 (n=63). 260

medRxiv preprint doi: https://doi.org/10.1101/2022.03.17.22272572; this version posted March 18, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

262 References

Ly KN, Hughes EM, Jiles RB, Holmberg SD. Rising Mortality Associated With 263 1. Hepatitis C Virus in the United States, 2003-2013. Clin Infect Dis. May 15 2016;62(10):1287-264 265 1288. doi:10.1093/cid/ciw111 Survaprasad AG, White JZ, Xu F, et al. Emerging epidemic of hepatitis C virus 266 2. infections among young nonurban persons who inject drugs in the United States, 2006-2012. 267 Clin Infect Dis. Nov 2014;59(10):1411-9. doi:10.1093/cid/ciu643 268 Onofrey S, Aneja J, Haney GA, et al. Underascertainment of acute hepatitis C virus 269 3. 270 infections in the U.S. surveillance system: a case series and chart review. Ann Intern Med. 271 Aug 18 2015;163(4):254-61. doi:10.7326/m14-2939 272 Mathei C, Van Dooren S, Lemey P, Van Damme P, Buntinx F, Vandamme AM. The 4. epidemic history of hepatitis C among injecting drug users in Flanders, Belgium. J Viral 273 Hepat. Jun 2008;15(6):399-408. doi:10.1111/j.1365-2893.2007.00950.x 274 Caraballo Cortes K, Rosinska M, Janiak M, et al. Next-generation sequencing 275 5. 276 analysis of a cluster of hepatitis C virus infections in a haematology and oncology center. 277 PLoS One. 2018;13(3):e0194816. doi:10.1371/journal.pone.0194816 Jacka B, Applegate T, Krajden M, et al. Phylogenetic clustering of hepatitis C virus 278 6. 279 among people who inject drugs in Vancouver, Canada. Hepatology. Nov 2014;60(5):1571-1580. doi:10.1002/hep.27310 280 281 7. Tamura K, Nei M, Kumar S. Prospects for inferring very large phylogenies by using 282 the neighbor-joining method. Proc Natl Acad Sci U S A. Jul 27 2004;101(30):11030-5. 283 doi:10.1073/pnas.0404206101 284 8. Rothenberg RB, Long DM, Sterk CE, et al. The Atlanta Urban Networks Study: a 285 blueprint for endemic transmission. AIDS. Sep 29 2000;14(14):2191-200. doi:10.1097/00002030-200009290-00016 286 Rhodes T. Risk environments and drug harms: a social science for harm reduction 287 9. approach. Int J Drug Policy. May 2009;20(3):193-201. doi:10.1016/j.drugpo.2008.10.003 288 van Beek I, Dwyer R, Dore GJ, Luo K, Kaldor JM. Infection with HIV and hepatitis C 289 10. virus among injecting drug users in a prevention setting: retrospective cohort study. BMJ. 290 291 Aug 15 1998;317(7156):433-7. doi:10.1136/bmj.317.7156.433 292 11. Hagan H, McGough JP, Thiede H, Weiss NS, Hopkins S, Alexander ER. Syringe 293 exchange and risk of infection with hepatitis B and C viruses. Am J Epidemiol. Feb 01 294 1999;149(3):203-13. doi:10.1093/oxfordjournals.aje.a009792 295 Strasfeld L, Lo Y, Netski D, Thomas DL, Klein RS. The association of hepatitis C 12. 296 prevalence, activity, and genotype with HIV infection in a cohort of New York City drug 297 users. J Acquir Immune Defic Syndr. Jul 01 2003;33(3):356-64. doi:10.1097/00126334-298 200307010-00010 299 Falade-Nwulia O, Hackman J, Mehta SH, et al. Factors associated with phylogenetic 13. 300 clustering of hepatitis C among people who inject drugs in Baltimore. BMC Infect Dis. Nov 10 2020;20(1):815. doi:10.1186/s12879-020-05546-x 301 302 Ramachandran S, Thai H, Forbi JC, et al. A large HCV transmission network enabled 14. 303 a fast-growing HIV outbreak in rural Indiana, 2015. EBioMedicine. Nov 2018;37:374-381. 304 doi:10.1016/j.ebiom.2018.10.007 Sacks-Davis R, Daraganova G, Aitken C, et al. Hepatitis C virus phylogenetic 305 15. 306 clustering is associated with the social-injecting network in a cohort of people who inject drugs. PLoS One. 2012;7(10):e47335. doi:10.1371/journal.pone.0047335 307 308 16. Kaplan EH. Needles that kill: modeling human immunodeficiency virus transmission via shared drug injection equipment in shooting galleries. Rev Infect Dis. 1989 Mar-Apr 309 310 1989;11(2):289-98. doi:10.1093/clinids/11.2.289 Tumpney M, John B, Panneer N, et al. Human Immunodeficiency Virus (HIV) 311 17. Outbreak Investigation Among Persons Who Inject Drugs in Massachusetts Enhanced by 312 HIV Sequence Data. J Infect Dis. 09 02 2020;222(Suppl 5):S259-S267. 313 doi:10.1093/infdis/jiaa053 314